SI1297013T1 - Uporaba TACI kot protitumorskega sredstva - Google Patents

Uporaba TACI kot protitumorskega sredstva

Info

Publication number
SI1297013T1
SI1297013T1 SI200130650T SI200130650T SI1297013T1 SI 1297013 T1 SI1297013 T1 SI 1297013T1 SI 200130650 T SI200130650 T SI 200130650T SI 200130650 T SI200130650 T SI 200130650T SI 1297013 T1 SI1297013 T1 SI 1297013T1
Authority
SI
Slovenia
Prior art keywords
taci
mammal
tumor agent
reagent
administering
Prior art date
Application number
SI200130650T
Other languages
English (en)
Inventor
Christine Ambrose
Jeffrey Thompson
Pascal Schneider
Paul Rennert
Original Assignee
Biogen Idec Inc
Apoxis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Apoxis Sa filed Critical Biogen Idec Inc
Publication of SI1297013T1 publication Critical patent/SI1297013T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200130650T 2000-04-27 2001-04-27 Uporaba TACI kot protitumorskega sredstva SI1297013T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19994600P 2000-04-27 2000-04-27
PCT/US2001/040626 WO2001081417A2 (en) 2000-04-27 2001-04-27 Use of taci as an anti-tumor agent
EP01927474A EP1297013B1 (en) 2000-04-27 2001-04-27 Use of taci as an anti-tumor agent

Publications (1)

Publication Number Publication Date
SI1297013T1 true SI1297013T1 (sl) 2007-06-30

Family

ID=22739664

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130650T SI1297013T1 (sl) 2000-04-27 2001-04-27 Uporaba TACI kot protitumorskega sredstva

Country Status (13)

Country Link
EP (1) EP1297013B1 (sl)
JP (1) JP2004513876A (sl)
AT (1) ATE336509T1 (sl)
AU (2) AU5392001A (sl)
CA (1) CA2404945C (sl)
CY (1) CY1105788T1 (sl)
DE (1) DE60122337T2 (sl)
DK (1) DK1297013T3 (sl)
ES (1) ES2271004T3 (sl)
NZ (1) NZ521629A (sl)
PT (1) PT1297013E (sl)
SI (1) SI1297013T1 (sl)
WO (1) WO2001081417A2 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
WO2002016412A2 (en) 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2002046231A2 (en) * 2000-12-07 2002-06-13 The University Of British Columbia Caml-binding peptides
AU2002311976A1 (en) 2001-05-24 2002-12-03 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
KR101021124B1 (ko) * 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
ES2538469T3 (es) 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
CA2554526A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
ZA200801354B (en) * 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
ATE453712T1 (de) * 1999-01-07 2010-01-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Also Published As

Publication number Publication date
DK1297013T3 (da) 2006-12-27
CA2404945A1 (en) 2001-11-01
AU2001253920B2 (en) 2006-03-16
CY1105788T1 (el) 2011-02-02
DE60122337T2 (de) 2007-08-16
JP2004513876A (ja) 2004-05-13
WO2001081417A3 (en) 2002-06-20
EP1297013B1 (en) 2006-08-16
NZ521629A (en) 2004-05-28
DE60122337D1 (de) 2006-09-28
ATE336509T1 (de) 2006-09-15
CA2404945C (en) 2010-02-09
AU5392001A (en) 2001-11-07
ES2271004T3 (es) 2007-04-16
PT1297013E (pt) 2006-12-29
WO2001081417A2 (en) 2001-11-01
EP1297013A2 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
SI1297013T1 (sl) Uporaba TACI kot protitumorskega sredstva
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
HK1045852A1 (en) Polyurethane solutions containing alkoxysilane structural units
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
GB9915437D0 (en) Chemical compounds III
BG102259A (en) Compostions with controlled paroxetine release
YU52099A (sh) Fungicidni trifluormetilalkilamino-triazolpirimidini
ZA200006733B (en) Compositions comprising organic mono- or dinitrate for treating impotence.
TW200603785A (en) Compositions containing reduced coenzyme Q10 and carotenoid
AU5547501A (en) Method of reducing side effects of chemotherapy in cancer patients
PL343176A1 (en) Fungicidal 6-(2-halo-4-alkoxyphenyl)-triazolopyrimidines
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
GR3036142T3 (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
AU2001260077A1 (en) Microfiltration using activated carbon
AU2003213661A8 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
MXPA06009711A (es) Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.
GB9924941D0 (en) Treatment of dyskinesia
EP1746106A3 (en) Use of TACI as an anti-tumor agent
SI1244614T1 (sl) Triptazni inhibitorji
WO2006119402A3 (en) C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
WO2004031347A3 (en) Methods and compositions for soluble cpg15